Sanwa Kagaku Kenkyusho

Focus: Sanwa Kagaku Kenkyusho is a Japan-based diagnostics and small molecule drug developer focused on metabolic, endocrine, renal, dermatologic, and respiratory diseases. The company maintains an active pipeline across multiple therapeutic areas with a mix of proprietary and licensed compounds.

Metabolic Diseases Endocrinology Nephrology Dermatology

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About Sanwa Kagaku Kenkyusho

AI assessmentNot Hiring

No open roles listed right now. Follow Sanwa Kagaku Kenkyusho to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

9 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

[14C]-SK-1404

Nocturia

Phase 1

Clinical Trials (1)

NCT02878096Bioavailability of [14C]-SK-1404 ADME & IV Microtracer Study

Phase 1

Help build intelligence for Sanwa Kagaku Kenkyusho

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to a diverse pipeline with 19 active trials spanning Phase 1 through Phase 3, providing exposure to multiple disease areas and drug development stages
Focus on underserved therapeutic niches (uremic pruritus, nocturia, secondary hyperparathyroidism) where commercial success could be significant despite smaller populations
Presence in Japan's home market provides career stability in a developed healthcare system with strong regulatory frameworks

Watch Out For

Zero active job openings at time of analysis indicates potential hiring freeze or limited expansion, reducing near-term career mobility within the company
Heavy reliance on Phase 3 programs (9 of 19 trials) creates concentrated binary risk—multiple program failures could destabilize the pipeline and workforce
Limited public information on financials, R&D intensity, and company size makes it difficult to assess runway, cash position, and long-term stability

Generated by Claude from Sanwa Kagaku Kenkyusho's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

[14C]-SK-1405

Pruritus

Phase 1

Clinical Trials (1)

NCT02846181A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-SK-1405

Phase 1

SK-1405

Pruritus

Phase 1

Clinical Trials (1)

NCT02650076A Study to Investigate the Receptor Occupancy of SK-1405 in Healthy, Caucasian, Male Subjects

Phase 1